COVID-19 Vaccine Trial Put on Hold Over Safety Concerns
After a study participant in the United Kingdom fell ill, AstraZeneca said in a statement that it would review safety and efficacy data. Then the company released a second statement, saying it initiated the pause even though the study participant is expected to make a full recovery, according to STAT News.
Despite the pause, adverse reactions are very common in clinical trials as is pausing for a safety and efficacy review. It also does not mean the vaccine candidate is a failure. However, it does make it increasingly unlikely that the vaccine will be approved and ready for distribution by Election Day, as President Trump has often said a vaccine would be.
In a statement, according to The New York Times, AstraZeneca described the pause as a "routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
AstraZeneca was not clear about how long the pause in the vaccine trial will last. The late-stage vaccine trial so far has included 17,000 people in Europe, the U.S., Brazil and South Africa, according to The Guardian. Phase 3 trials include a large number of study participants for exactly this reason; only by testing a large number of people do rare side-effects emerge.
"This is the whole point of doing these Phase 2, Phase 3 trials," said Dr. Phyllis Tien, an infectious disease physician at the University of California, San Francisco, as The New York Times reported. "We need to assess safety, and we won't know the efficacy part until much later. I think halting the trial until the safety board can figure out whether or not this was directly related to the vaccine is a good idea."
While the exact condition that the study participant suffered has not been released, The New York Times is reporting that sources are saying the person received a diagnosis of transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. It's unclear if the diagnosis is directly related to the vaccine candidate or not.
Robert Booy, a University of Sydney professor of vaccinology, told The Guardian that if the sickness is unrelated to the vaccine candidate then the trial might be paused for just one week, but it may extend to one month. He said that the pause "is more likely the product of being super careful" rather than a problem with the vaccine.
"This could have just been a high fever and it turns out they've got appendicitis," he said. "My bet would be that they find something in this participant that is not causal [from the vaccine]. It'll take them about one to two weeks to ascertain this, and then they will probably restart the trial in a month."
AstraZeneca said in a statement that it was "working to expedite the review of the single event to minimize any potential impact on the trial timeline," and did not waver from its commitment "to the safety of our participants and the highest standards of conduct in our trials," as The New York Times reported.
AstraZeneca was one of nine companies that signed a pledge Tuesday to assure the public that a vaccine would not be rushed due to politics. In a rare move, nine companies working on a vaccine made a joint pledge to "stand with science" and insisted that they would not be rolled out prematurely without proving beyond a doubt that they are safe and effective, according to The New York Times.
- U.S. Sits out as World Leaders Pledge $8 Billion to Find a COVID-19 ... ›
- Pfizer Coronavirus Vaccine Enters Phase 2 and 3 Clinical Trials ... ›
- Russia Approves World's First Coronavirus Vaccine After Less Than ... ›
- Trump Orders Hospitals to Stop Sending COVID-19 Data to CDC ... ›
- First Trial of Moderna's Coronavirus Vaccine Produces Immune ... ›
- Moderna, Pfizer Release Study Designs as Vaccine Distrust Grows Among Americans - EcoWatch ›
- Johnson & Johnson Pauses COVID-19 Vaccine Trial After Mystery Illness - EcoWatch ›
By Julia Conley
Representing more than 17,000 claimants who support climate action, the international organization Friends of the Earth on Tuesday opened its case against fossil fuel giant Shell at The Hague by demanding that a judge order the corporation to significantly reduce its carbon emissions in the next decade.
EcoWatch Daily Newsletter
Eat Just's cultured chicken has been approved for sale in Singapore as an ingredient in chicken bites. Eat Just
- Most Meat Will Be Plant-Based or Lab-Grown in 20 Years, Analysts ... ›
- Slaughter-Free Lab Grown Steak Cast As Ethically Friendly Alternative ›
- FDA Takes First Steps to Regulating Lab-Grown Meat - EcoWatch ›
- Tyson Foods Invests in 'Clean Meat' - EcoWatch ›
The world's largest sand island has been on fire for the past six weeks due to a campfire, and Australia's firefighters have yet to prevent flames from destroying the fragile ecosystem.
By Jessica Corbett
A national nonprofit revealed Tuesday that testing commissioned by the group as well as separate analysis conducted by Massachusetts officials show samples of an aerially sprayed pesticide used by the commonwealth and at least 25 other states to control mosquito-borne illnesses contain toxic substances that critics call "forever chemicals."
- How Will the Biden Administration Tackle 'Forever Chemicals ... ›
- Are Forever Chemicals Harming Ocean Life? - EcoWatch ›
- How Chemicals Like PFAS Can Increase Your Risk of Severe ... ›
The government of New Zealand declared a climate emergency on Wednesday, a symbolic step recognizing the Intergovernmental Panel on Climate Change (IPCC) predictions of substantial global warming if emissions do not fall.